Trial Search Results

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Device: MammaPrint


Inclusion Criteria:

   - Women with histologically proven invasive stage I-II, node negative, hormone receptor
   positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score

   - ≥ 18 years of age at time of consent

   - Written informed consent

Exclusion Criteria:

   - Insufficient tissue remaining for Mammaprint FFPE

   - Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria

   - Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Annabel Castaneda
Not Recruiting